HommerA., Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/ timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol2007; 17: 53–62.
2.
SchachatA.P., ChambersW.A., LiesegangT.J., AlbertD.A.Safe and effective. Ophthalmology2003; 110: 2073–4.
Committee for Proprietary Medicinal Products (CPMP). Points to consider on switching between superiority and non-inferiority. CPMP/EWP/482/99. London; 2000. Available at: http://www.emea.europa.eu/pdfs/human/ewp/048299en.pdf.
5.
DiestelhorstM., LarssonL.I.A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology2006; 113: 70–6.
6.
HughesB.A., BacharachJ., CravenE.R.A threemonth, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma2005; 14: 392–9.
7.
DiestelhorstM., LarssonL.I.A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol2004; 88: 199–203.
